Generic Medicine Info
Indications and Dosage
Myelodysplastic disease
Adult: Initially, 75 mg/m2 daily via SC inj or IV infusion over 10-40 min for 7 days, followed by a rest period of 21 days (28-day cycle), may be increased to 100 mg/m2 daily if there is no benefit after 2 cycles, and no toxicity other than nausea and vomiting has occurred. Recommended treatment duration: Min of 4 to 6 cycles; continued as long as the patient benefits, or until disease progression. Dose adjustment may be needed for haematological toxicity.
Renal Impairment
Reduce dose by 50% on the next cycle if serum bicarbonate falls to <20 mmol/L. Delay next treatment cycle if serum creatinine or BUN is >2 times the baseline value and above the upper limit of normal (ULN) until values return to normal or baseline, and then reduce dose by 50% on the next cycle.
IV: Add 10 mL of sterile water for inj to a vial containing 100 mg to obtain a final concentration of 10 mg/mL. Shake vigorously until soln is dissolved and clear. Further dilute reconstituted soln w/ 50-100 mL of NaCl 0.9% or lactated Ringer's inj for IV infusion. SC: Slowly add 4 mL of sterile water for inj to a vial containing 100 mg to obtain a final concentration of 25 mg/mL. Shake vigorously until a susp is formed (susp will be cloudy).
Incompatible w/ dextrose 5% soln, hetastarch, glucose- or bicarbonate-containing soln.
Advanced malignant hepatic tumour. Pregnancy and lactation.
Special Precautions
Patient w/ high tumour burden, history of severe CHF, clinically unstable cardiac disease or pulmonary disease. Renal and severe hepatic impairment.
Adverse Reactions
Significant: Nausea and vomiting, anaemia, neutropenia, thrombocytopenia, GI or intracranial haemorrhage, hepatotoxicity, renal tubular acidosis, elevated serum creatinine, inj site reactions (e.g. erythema, pain).
Nervous: Insomnia, headache, fatigue, dizziness, anxiety.
GI: Abdominal pain, anorexia, constipation, diarrhoea, dyspepsia, mucositis.
Resp: Dyspnoea.
Hepatic: Elevated LFT.
Endocrine: Hypokalaemia.
Haematologic: Bruising, petechiae.
Dermatologic: Rash, itch, alopecia.
Immunologic: Infection, hypersensitivity reactions.
Others: Fever.
Potentially Fatal: Progressive hepatic coma, renal failure, tumour lysis syndrome, necrotising fasciitis.
IV/Parenteral/SC: D
Patient Counseling Information
This drug may cause fatigue, if affected, do not drive or operate machinery.
Monitoring Parameters
Monitor LFT, CBC, electrolytes, serum creatinine and bicarbonate at baseline and before each treatment cycle, and as clinically indicated. Monitor for bleeding, nausea and vomiting, and inj site reactions. Consider cardiopulmonary assessment prior to and during treatment.
Symptoms: Nausea, vomiting, diarrhoea. Management: Supportive treatment.
Mechanism of Action: Azacitidine, a synthetic pyrimidine nucleoside analog of cytidine, is believed to exert its antineoplastic effects by inhibiting DNA methyltransferase (the enzyme responsible for methylating newly synthesised DNA in mammalian cells) thereby causing hypomethylation of DNA and by direct toxicity on abnormal hematopoietic cells in the bone marrow.
Absorption: Rapidly and completely absorbed (SC). Bioavailability: Approx 89% (SC). Time to peak plasma concentration: 30 min (SC).
Distribution: Volume of distribution: 76 ± 26 L (IV).
Metabolism: Metabolised in the liver via spontaneous hydrolysis and deamination by cytidine deaminase into several metabolites.
Excretion: Mainly via urine, approx 50% (SC) and 85% (IV), as metabolites; faeces (<1%). Elimination half-life: Approx 4 hr.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Azacitidine, CID=9444, (accessed on Jan. 21, 2020)

Store at 25°C.
This is a cytotoxic drug. Follow applicable procedures for receiving, handling, admin, and disposal.
MIMS Class
Cytotoxic Chemotherapy
ATC Classification
L01BC07 - azacitidine ; Belongs to the class of antimetabolites, pyrimidine analogues. Used in the treatment of cancer.
Anon. Azacitidine . Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 14/06/2017.

Azacitidine for Injection, Powder, Lyophilized, for Solution (Seton Pharmaceuticals). DailyMed. Source: U.S. National Library of Medicine. Accessed 14/06/2017.

Buckingham R (ed). Azacitidine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 14/06/2017.

Joint Formulary Committee. Azacitidine. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 14/06/2017.

McEvoy GK, Snow EK, Miller J et al (eds). Azacitidine . AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 14/06/2017.

Disclaimer: This information is independently developed by MIMS based on Azacitidine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
  • Azadine
  • Vidaza
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in